Related Experiment Video
Updated: Aug 29, 2026
Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells
Published on: May 9, 2025
Bioassay using epidermal keratinocytes to determine phosphorylation status of the epidermal growth factor receptor in
Corazon D Bucana1, Isaiah J Fidler
1Department of Cancer Biology, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA.
Abstract:
We developed a bioassay to evaluate the phosphorylation status of a fibrosarcoma following systemic administration of the protein tyrosine kinase inhibitor PKI 166. Samples of subcutaneous fibrosarcomas and distant skin were fixed in formalin, sectioned, and stained with several fluorescent antibodies against the epidermal growth factor receptor (EGF-R) and phosphorylated EGF-R. In mice given different doses of PKI 166, the dose-dependent inhibition of phosphorylation of EGF-R in epidermal keratinocytes paralleled that in fibrosarcomas growing subcutaneously, suggesting that skin biopsies can be used as surrogate tissues for distant neoplasms to determine the phosphorylation status of protein tyrosine kinase receptors.
Insights
This study shows that skin biopsies can monitor protein tyrosine kinase inhibitor effectiveness in fibrosarcomas. This suggests skin can act as a surrogate tissue for evaluating drug responses in distant tumors.
Area of Science:
- Oncology
- Pharmacology
- Biochemistry
Background:
- Protein tyrosine kinase inhibitors are crucial in cancer therapy.
- Evaluating drug efficacy in solid tumors can be challenging.
- Epidermal Growth Factor Receptor (EGF-R) phosphorylation is a key target.
Purpose of the Study:
- To develop a bioassay for assessing fibrosarcoma phosphorylation status after PKI 166 treatment.
- To determine if skin biopsies can serve as surrogate tissues for monitoring drug effects.
Main Methods:
- Systemic administration of protein tyrosine kinase inhibitor PKI 166 to mice with fibrosarcomas.
- Collection and fixation of fibrosarcoma and skin samples.
- Immunofluorescence staining for EGF-R and phosphorylated EGF-R.
Main Results:
- PKI 166 demonstrated dose-dependent inhibition of EGF-R phosphorylation.
- Inhibition patterns in epidermal keratinocytes mirrored those in fibrosarcomas.
- A parallel dose-dependent inhibition was observed in both tissues.
Conclusions:
- Skin biopsies can accurately reflect the phosphorylation status of distant fibrosarcomas.
- Skin serves as a viable surrogate tissue for monitoring protein tyrosine kinase receptor inhibition.
- This bioassay facilitates evaluating therapeutic responses to kinase inhibitors.
More Related Videos
Related Concept Videos
02:38Mitogens and the Cell Cycle
01:19Clinical Applications of Epidermal Stem Cells